Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 + Topotecan in Relapsed/Refractory SCLC
NCT00397293Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Nov 2006
- Primary completion
- Dec 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in small cell lung cancer (SCLC), sponsored by Ascenta Therapeutics. Started Nov 2006; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00397293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397293.